5245582026-07-012026-09-305245582026-09-305245582026-03-315245582026-04-012026-09-305245582026-07-012026-09-30in-capmkt:OtherExpenses1Member5245582026-07-012026-09-30in-capmkt:OtherExpenses2Member5245582026-04-012026-09-30in-capmkt:OtherExpenses1Member5245582026-04-012026-09-30in-capmkt:OtherExpenses2Member5245582026-09-30OtherNoncurrentFinancialAssetsDomain15245582026-09-30OtherNoncurrentAssetsDomain15245582026-09-30OtherNoncurrentAssetsDomain25245582026-09-30OtherNoncurrentAssetsDomain35245582026-09-30OtherNoncurrentAssetsDomain45245582026-09-30OtherCurrentFinancialAssetsDomain15245582026-09-30OtherCurrentFinancialAssetsDomain25245582026-09-30OtherCurrentAssetsDomain15245582026-09-30OtherCurrentAssetsDomain25245582026-09-30OtherCurrentAssetsDomain35245582026-09-30OtherCurrentAssetsDomain45245582026-09-30OtherCurrentFinancialLiabilitiesDomain15245582026-09-30OtherCurrentFinancialLiabilitiesDomain25245582026-09-30OtherCurrentFinancialLiabilitiesDomain35245582026-09-30OtherCurrentFinancialLiabilitiesDomain45245582026-09-30OtherCurrentFinancialLiabilitiesDomain55245582026-09-30OtherCurrentFinancialLiabilitiesDomain65245582026-09-30OtherCurrentLiabilitiesDomain15245582026-09-30OtherCurrentLiabilitiesDomain25245582026-09-30OtherCurrentLiabilitiesDomain35245582026-07-012026-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15245582026-04-012026-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15245582026-07-012026-09-30ItemsThatWillBeReclassifiedToProfitAndLoss15245582026-04-012026-09-30ItemsThatWillBeReclassifiedToProfitAndLoss15245582026-07-012026-09-30AuditorDomain1iso4217:INRiso4217:INRxbrli:shares524558NEULANDLABNOTLISTEDINE794A01010NEULAND LABORATORIES LIMITEDMain BoardEquity2026-04-012027-03-312026-11-032026-10-22INRLakhsQuarterlySecond quarterSingle segmentManufacturing of Active Pharmaceuticals2026-11-0309:30:002026-11-0315:34:00trueCash Flow IndirectDeclaration of unmodified opinion2026-07-012026-09-30UnauditedConsolidated449656900074953000457152200021578730000-64731500010175870007307300028771300099280900038817400006897820000689782000178679000-514700017353200005162500000000516250000-3512000512738000516270000051273800001290050001040.2440.240040.2440.241. The financial results for the quarter and half year ended September 30, 2026, have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on November 03, 2026.The Statutory auditor have issued an unmodified opinion in respect of the limited review for the quarter and half year ended September 30, 2026. <br /> <br /> 2. The financial results have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard (Ind AS) 34, "Interim Financial Reporting", prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India, and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. <br /> <br /> 3. The consolidated financial results include results of the following wholly owned subsidiaries: <br /> (a) Neuland Laboratories Inc., USA <br /> (b) Neuland Laboratories KK., Japan. <br /> <br /> 4. Segment Reporting <br /> <br /> i. Segment information presented for the "Consolidated financial results" as permitted under the Ind AS - 'Operating Segments'. <br /> <br /> ii. The management has assessed the identification of reportable segments in accordance with the requirements of Ind AS 108 ‘Operating Segment’ and believes that the Group has only one reportable segment namely "manufacture of active pharmaceutical ingredients and allied services”. Geography-wise details of the Company’s revenues from external customers and its non-current assets (excluding financial assets) are disclosed above. <br /> <br /> 5. The EPS for quarters has not been annualised. <br /> 2026-04-012026-09-30UnauditedConsolidated109123400001598700001107221000044455650000-724769000208187900014279200055334500019051460008403958000266825200002668252000687482000-122110006752710000199298100000001992981000-44020001988579000199298100001988579000012900500010155.34155.3400155.34155.34Manufacturing expenses578043000Other expenses414766000Manufacturing expenses1057400000Other expenses847746000994191300028429540000279461000038616000456400000198220000013900200015882400006155720001639705300055210020000294304000053655400039678280000145436000759285800007846700001389853000000302955830001290050002016809100020297096000020297096000296331200000029633120001694860006799250000381272300045976000014517900019409830002086162000112666000036725820002363011000309370001192340000618576400000999848700030295583000Security deposits139002000Prepaid expenses1889000Capital advances (Refer Note 40)589723000Balances with government authorities2337000Income tax assets (net)21623000Interest accrued on bank deposits101860000Unbilled revenue43576000Prepaid expenses211383000Advance to suppliers179381000Balances with government authorities314730000Export benefits receivable79176000Interest accrued but not due on borrowings397000Interest accrued on micro enterprises and small enterprises payable1212000Unclaimed dividends2173000Capital creditors209184000Employee benefits payable (Refer Note 39)301636000Accrual for expenses612058000Advance from customers2266734000Liability towards Corporate Social Responsibility ('CSR') expenditure17968000Statutory liabilities78309000142793000-41813800024608840000-62766000-352000-19520000-316930000-5874420000-16876500005533450000159770000-392120000-3653900001598620000002354000003709000016759590004344211000000728606000036156050000000000022050002605989000000000000000000000896550000-1185038000-36991670000000000067940400022895300015556000436217000959720000-47012000-144306000-227868000-2282000-230150000766704000536554000Re-measurement gain on defined benefit plans-2757000-2757000Re-measurement gain on defined benefit plans-2757000-2757000-694000-694000Exchange differences in translating the financial statements of foreign operations-1449000-1449000Exchange differences in translating the financial statements of foreign operations-2339000-233900000-3512000-4402000UnauditedtrueM S K A & Associates LLP, Chartered Accountantstrue2027-07-31